← Eichor
Condition: Scleroderma Systemic Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Scleroderma Systemic

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Periodontal Microbiota in Systemic Sclerosis
NA · 1 location(s) · University Hospital, Strasbourg, France · NCT06182293Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammato
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06599411US Zamto-cel Autoimmune Diseases
Phase 1 · 1 location(s) · Miltenyi Biomedicine GmbH · NCT06708845Study of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis
NA · 5 location(s) · Primus Pharmaceuticals · NCT06256575A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
Phase 1 · 14 location(s) · CRISPR Therapeutics · NCT06925542A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
Phase 1 · 2 location(s) · Beijing GoBroad Hospital · NCT06980597Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel
EARLY_Phase 1 · 1 location(s) · Changhai Hospital · NCT07246096Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
Phase 1/Phase 2 · 1 location(s) · Peking University Third Hospital · NCT06828042Home-Based Clinical Management of Cardiac Complications in Systemic Sclerosis
Phase N/A · 1 location(s) · Oslo University Hospital · NCT06865118Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases
Phase N/A · 1 location(s) · University Hospital, Toulouse · NCT05251415Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
Phase 2 · 92 location(s) · Novartis Pharmaceuticals · NCT06655896CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07315087Patients Diagnosed With Scleroderma: Physical Performance and Functionality
Phase N/A · 1 location(s) · Hacettepe University · NCT07183072Medical Follow-up of New Cases of Polyarthritis in Children and Young Adults
Phase N/A · 1 location(s) · Université Catholique de Louvain · NCT07000916A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT07104721Home Based Clinical Management of Interstitial Lung Disease in Systemic Rheumatic Diseases
NA · 1 location(s) · Oslo University Hospital · NCT06732674Evaluation of HRCT Patterns in Systemic Sclerosis-associated Interstitial Lung Disease
Phase N/A · 1 location(s) · Central Hospital, Nancy, France · NCT05482607Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis
Phase 2 · 9 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06375005Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.
Phase 1/Phase 2 · 1 location(s) · Beijing GoBroad Hospital · NCT06947473New Orleans Pulmonary Hypertension Biobank
Phase N/A · 1 location(s) · Louisiana State University Health Sciences Center in New Orl · NCT03269630A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT06978647RY_SW01 Cell Injection Therapy in Systemic Sclerosis
Phase 1/Phase 2 · 1 location(s) · Jiangsu Renocell Biotech Company · NCT06058091ILD-SARDs Registry and Biorepository
Phase N/A · 1 location(s) · McGill University Health Centre/Research Institute of the Mc · NCT05007340CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
Phase 1 · 1 location(s) · The Children's Hospital of Zhejiang University School of Med · NCT07305116Deployment o the Multidisciplinary Prospective Cohort Imminent
NA · 1 location(s) · University Hospital, Lille · NCT04334031CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06941129A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Disease
Phase 1 · 28 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT07115745A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
Phase 2 · 76 location(s) · argenx · NCT06655155Patients Diagnosed With Scleroderma and Their Chewing and Swallowing Performance
Phase N/A · 1 location(s) · Hacettepe University · NCT07182981Sildenafil for Early Pulmonary Vascular Disease in Scleroderma
Phase 2 · 2 location(s) · Johns Hopkins University · NCT04797286
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.